Pressroom

Herpes Vaccine Enters Early-Stage Clinical Trial in Australia; Scientists Hope for HSV-2 Cure

Source: Medical Daily

By: Weiss, Jonathan

07/17/2013

Coridon, an Australian biotechnology company, will commence early-stage, Phase I human trials of its herpes simplex 2 (HSV-2) vaccine. The HSV-2 vaccine would be used as a preventive vaccine and a therapeutic vaccine for those already infected with genital herpes. Another HSV-2 vaccine has been developed by Genocea, which is pursuing clinical trials. GlaxoSmithKline’s vaccine, however, failed in late-stage clinical trials.



Copyright © 2014 Information, Inc.